Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal ketamine for suicidality in severe major depression awaiting ECT
2014-002451-26Phase 4Terminated
- Sponsor
- Department of Psychiatry, Helsinki University Hospital
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in major depressive disorder (MDD) and suicidal ideation comparing Intranasal ketamine with Intranasal placebo (2 arms). Primary endpoint: Reduction in suicidality (primary). Started Apr 2015; status: terminated.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)suicidal ideation
Beyond the preview
Go deeper on 2014-002451-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002451-26.